Ladophar boosts capital, expands business, addresses accumulated losses

Lam Dong Pharmaceutical JSC (Ladophar) is set to expand its business operations and strengthen its financial position following resolutions from an Extraordinary General Meeting in November 2025. The company will raise its charter capital from VND 133,381,670,000 to VND 187,271,670,000 by issuing 18,727,167 shares at a par value of VND 10,000 per share. This capital increase is primarily aimed at funding the CO2 ultra-high purity plant project, with VND 90,000,000,000 allocated to cover investment shortfalls and an additional VND 3,640,670,000 for working capital.

To address accumulated losses of VND 50,655,818,563 as of June 30, 2025, Ladophar plans to utilize VND 24,348,384,362 from its development investment fund and VND 5,390,000,000 from the share premium generated by a private placement in 2025. This strategy is projected to reduce the company's accumulated losses by approximately VND 20,917,434,201. The company also intends to diversify its business activities by adding "Retail of beverages in specialized stores" to its registered business lines, including alcoholic and non-alcoholic drinks.

Furthermore, Ladophar will augment its borrowing capacity for 2025, allowing for short- and long-term loans from individuals and other organizations to repay bond debts and other outstanding obligations. The company is also proposing to appoint an additional independent auditing firm, bringing the total to five, to ensure competitive and high-quality financial audits.